References

1. Ruiz-Irastorza, G.; Crowther, M.; Branch, W.; Khamashta, M.A. Antiphospholipid syndrome. Lancet 2010, 376, 1498–1509.
2. Cheng, C.; Cheng, G.Y.; Denas, G.; Pengo, V. Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review. Blood Rev. 2020, 100788.
3. Miyakis, S.; Lockshin, M.D.; Atsumi, T.; Branch, D.W.; Brey, R.L.; Cervera, R.; Derksen, R.H.; PG, D.E.G.; Koike, T.; Meroni, P.L.; et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006, 4, 295–306.
4. Hulstein, J.J.; Lenting, P.J.; de Laat, B.; Derksen, R.H.; Fijnheer, R.; de Groot, P.G. beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007, 110, 1483–1491.
5. van der Vorm, L.N.; Visser, R.; Huskens, D.; Veninga, A.; Adams, D.L.; Remijn, J.A.; Hemker, H.C.; Rensma, P.L.; van Horssen, R.; de Laat, B. Circulating active von Willebrand factor levels are increased in chronic kidney disease and end-stage renal disease. Clin. Kidney J. 2020, 13, 72–74.
6. Groot, E.; de Groot, P.G.; Fijnheer, R.; Lenting, P.J. The presence of active von Willebrand factor under various pathological conditions. Curr. Opin. Hematol. 2007, 14, 284–289.
7. Claus, R.A.; Bockmeyer, C.L.; Budde, U.; Kentouche, K.; Sossdorf, M.; Hilberg, T.; Schneppenheim, R.; Reinhart, K.; Bauer, M.; Brunkhorst, F.M.; et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb. Haemost. 2009, 101, 239–247.
8. Kawecki, C.; Lenting, P.J.; Denis, C.V. von Willebrand factor and inflammation. J. Thromb. Haemost. 2017, 15, 1285–1294.
9. O’Sullivan, J.M.; Ward, S.; Lavin, M.; O’Donnell, J.S. von Willebrand factor clearance—biological mechanisms and clinical significance. Br. J. Haematol. 2018, 183, 185–195.
10. Swami, A.; Kaur, V. von Willebrand Disease: A Concise Review and Update for the Practicing Physician. Clin. Appl. Thromb. Hemost. 2017, 23, 900–910.
11. Tanaka, H.; Nagai, Y.; Kuwabara, C.; Shimizu, R.; Umeki, A.; Yamamoto, T. Acquired von Willebrand Syndrome due to Aortic Valve Stenosis in a Case with Antiphospholipid Antibody. Intern. Med. 2018, 57, 1641–1644.
12. Simurda, T.; Dobrotova, M.; Skornova, I.; Sokol, J.; Kubisz, P.; Stasko, J. Successful Use of a Highly Purified Plasma von Willebrand Factor Concentrate Containing Little FVIII for the Long-Term Prophylaxis of Severe (Type 3) von Willebrand’s Disease. Semin. Thromb. Hemost. 2017, 43, 639–641.
13. Kremer Hovinga, J.A.; Coppo, P.; Lämmle, B.; Moake, J.L.; Miyata, T.; Vanhoorelbeke, K. Thrombotic thrombocytopenic purpura. Nat. Rev. Dis. Primers 2017, 3, 17020.
14. Brehm, M.A. Von Willebrand factor processing. Hamostaseologie 2017, 37, 59–72.
15. Karlaftis, V.; Perera, S.; Monagle, P.; Ignjatovic, V. Importance of post-translational modifications on the function of key haemostatic proteins. Blood Coagul. Fibrinolysis 2016, 27, 1–4.
16. Fazavana, J.; Brophy, T.M.; Chion, A.; Cooke, N.; Terraube, V.; Cohen, J.; Parng, C.; Pittman, D.; Cunningham, O.; Lambert, M.; et al. Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation. J. Thromb. Haemost. 2020, 18, 1278–1290.
17. McKinnon, T.A.; Chion, A.C.; Millington, A.J.; Lane, D.A.; Laffan, M.A. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood 2008, 111, 3042–3049.
18. Tischer, A.; Machha, V.R.; Moon-Tasson, L.; Benson, L.M.; Auton, M. Glycosylation sterically inhibits platelet adhesion to von Willebrand factor without altering intrinsic conformational dynamics. J. Thromb. Haemost. 2020, 18, 79–90.
19. Verweij, C.L.; Diergaarde, P.J.; Hart, M.; Pannekoek, H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 1986, 5, 1839–1847.
20. Haberichter, S.L. von Willebrand factor propeptide: Biology and clinical utility. Blood 2015, 126, 1753–1761.
21. Sadler, J.E. Biochemistry and genetics of von Willebrand factor. Annu. Rev. Biochem. 1998, 67, 395–424.
22. Randi, A.M.; Smith, K.E.; Castaman, G. von Willebrand factor regulation of blood vessel formation. Blood 2018, 132, 132–140.
23. Reinders, J.H.; de Groot, P.G.; Sixma, J.J.; van Mourik, J.A. Storage and secretion of von Willebrand factor by endothelial cells. Haemostasis 1988, 18, 246–261.
24. Slayter, H.; Loscalzo, J.; Bockenstedt, P.; Handin, R.I. Native conformation of human von Willebrand protein. Analysis by electron microscopy and quasi-elastic light scattering. J. Biol. Chem. 1985, 260, 8559–8563.
25. Flood, V.H.; Schlauderaff, A.C.; Haberichter, S.L.; Slobodianuk, T.L.; Jacobi, P.M.; Bellissimo, D.B.; Christopherson, P.A.; Friedman, K.D.; Gill, J.C.; Hoffmann, R.G.; et al. Crucial role for the VWF A1 domain in binding to type IV collagen. Blood 2015, 125, 2297–2304.
26. Szanto, T.; Vanhoorelbeke, K.; Toth, G.; Vandenbulcke, A.; Toth, J.; Noppe, W.; Deckmyn, H.; Harsfalvi, J. Identification of a VWF peptide antagonist that blocks platelet adhesion under high shear conditions by selectively inhibiting the VWF-collagen interaction. J. Thromb. Haemost. 2009, 7, 1680–1687.
27. Fidalgo, T.; Oliveira, A.; Silva Pinto, C.; Martinho, P.; Ferreira, G.; Salvado, R.; Sevivas, T.; Catarino, C.; Ribeiro, M.L. VWF collagen (types III and VI)-binding defects in a cohort of type 2M VWD patients—a strategy for improvement of a challenging diagnosis. Haemoph. Off. J. World Fed. Hemoph. 2017, 23, e143–e147.
28. Huizinga, E.G.; Martijn van der Plas, R.; Kroon, J.; Sixma, J.J.; Gros, P. Crystal structure of the A3 domain of human von Willebrand factor: Implications for collagen binding. Structure 1997, 5, 1147–1156.
29. Kumar, R.A.; Dong, J.F.; Thaggard, J.A.; Cruz, M.A.; López, J.A.; McIntire, L.V. Kinetics of GPIbalpha-vWF-A1 tether bond under flow: Effect of GPIbalpha mutations on the association and dissociation rates. Biophys. J. 2003, 85, 4099–4109.
30. Randi, A.M.; Rabinowitz, I.; Mancuso, D.J.; Mannucci, P.M.; Sadler, J.E. Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences. J. Clin. Investig. 1991, 87, 1220–1226.
31. Sixma, J.J.; Schiphorst, M.E.; Verweij, C.L.; Pannekoek, H. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur. J. Biochem. 1991, 196, 369–375.
32. Van der Vorm, L.N.; Li, L.; Huskens, D.; Chayoua, W.; Kelchtermans, H.; de Groot, P.G.; Roest, M.; Remijn, J.A.; de Laat, B. Analytical characterization and reference interval of an enzyme-linked immunosorbent assay for active von Willebrand factor. PLoS ONE 2019, 14, e0211961.
33. Furlan, M. Von Willebrand factor: Molecular size and functional activity. Ann. Hematol. 1996, 72, 341–348.
34. De Mast, Q.; Groot, E.; Asih, P.B.; Syafruddin, D.; Oosting, M.; Sebastian, S.; Ferwerda, B.; Netea, M.G.; de Groot, P.G.; van der Ven, A.J.A.M.; et al. ADAMTS13 Deficiency with Elevated Levels of Ultra-Large and Active von Willebrand Factor in P. falciparum and P. vivax Malaria. Am. J. Trop. Med. Hyg. 2009, 80, 492–498.
35. Sonneveld, M.A.; de Maat, M.P.; Leebeek, F.W. Von Willebrand factor and ADAMTS13 in arterial thrombosis: A systematic review and meta-analysis. Blood Rev. 2014, 28, 167–178.
36. Pickens, B.; Mao, Y.; Li, D.; Siegel, D.L.; Poncz, M.; Cines, D.B.; Zheng, X.L. Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. Blood 2015, 125, 3326–3334.
37. Masias, C.; Cataland, S.R. The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis. Blood 2018, 132, 903–910.
38. Verhenne, S.; Denorme, F.; Libbrecht, S.; Vandenbulcke, A.; Pareyn, I.; Deckmyn, H.; Lambrecht, A.; Nieswandt, B.; Kleinschnitz, C.; Vanhoorelbeke, K.; et al. Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice. Blood 2015, 126, 1715–1722.
39. Brait, V.H.; Miró-Mur, F.; Pérez-de-Puig, I.; Notario, L.; Hurtado, B.; Pedragosa, J.; Gallizioli, M.; Jiménez-Altayó, F.; Arbaizar-Rovirosa, M.; Otxoa-de-Amezaga, A.; et al. CD69 Plays a Beneficial Role in Ischemic Stroke by Dampening Endothelial Activation. Circ. Res. 2019, 124, 279–291.
40. Nimjee, S.M.; Dornbos, D., III; Pitoc, G.A.; Wheeler, D.G.; Layzer, J.M.; Venetos, N.; Huttinger, A.; Talentino, S.E.; Musgrave, N.J.; Moody, H.; et al. Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. Mol. Ther.J. Am. Soc. Gene Ther. 2019, 27, 1228–1241.
41. Sanders, Y.V.; Eikenboom, J.; de Wee, E.M.; van der Bom, J.G.; Cnossen, M.H.; Degenaar-Dujardin, M.E.; Fijnvandraat, K.; Kamphuisen, P.W.; Laros-van Gorkom, B.A.; Meijer, K.; et al. Reduced prevalence of arterial thrombosis in von Willebrand disease. J. Thromb. Haemost. 2013, 11, 845–854.
42. Chen, J.; Chung, D.W. Inflammation, von Willebrand factor, and ADAMTS13. Blood 2018, 132, 141–147.
43. Lindsey, N.J.; Dawson, R.A.; Henderson, F.I.; Greaves, M.; Hughes, P. Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome. Br. J. Rheumatol. 1993, 32, 123–126.
44. Der, H.; Kerekes, G.; Veres, K.; Szodoray, P.; Toth, J.; Lakos, G.; Szegedi, G.; Soltesz, P. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 2007, 16, 497–503.
45. Wurm, H. beta 2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int. J. Biochem. 1984, 16, 511–515.
46. Ng, C.J.; McCrae, K.R.; Ashworth, K.; Sosa, L.J.; Betapudi, V.; Manco-Johnson, M.J.; Liu, A.; Dong, J.F.; Chung, D.; White-Adams, T.C.; et al. Effects of anti-beta2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity. Res. Pract. Thromb. Haemost. 2018, 2, 380–389.
47. Hantgan, R.R. Fibrin protofibril and fibrinogen binding to ADP-stimulated platelets: Evidence for a common mechanism. Biochim. Biophys. Acta 1988, 968, 24–35.
48. Bennett, J.S.; Vilaire, G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J. Clin. Investig. 1979, 64, 1393–1401.
49. Ni, H.; Denis, C.V.; Subbarao, S.; Degen, J.L.; Sato, T.N.; Hynes, R.O.; Wagner, D.D. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J. Clin. Investig. 2000, 106, 385–392.
50. Nieswandt, B.; Watson, S.P. Platelet-collagen interaction: Is GPVI the central receptor? Blood 2003, 102, 449–461.
51. Schonberger, T.; Ziegler, M.; Borst, O.; Konrad, I.; Nieswandt, B.; Massberg, S.; Ochmann, C.; Jurgens, T.; Seizer, P.; Langer, H.; et al. The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischemia in mice. Am. J. Physiol. Cell Physiol. 2012, 303, C757–C766.
52. Law, D.A.; DeGuzman, F.R.; Heiser, P.; Ministri-Madrid, K.; Killeen, N.; Phillips, D.R. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature 1999, 401, 808–811.
53. Ayoub, M.A. Small molecules targeting heterotrimeric G proteins. Eur. J. Pharm. 2018, 826, 169–178.
54. Offermanns, S. Activation of Platelet Function Through G Protein–Coupled Receptors. Circ. Res. 2006, 99, 1293–1304.
55. Vassilatis, D.K.; Hohmann, J.G.; Zeng, H.; Li, F.; Ranchalis, J.E.; Mortrud, M.T.; Brown, A.; Rodriguez, S.S.; Weller, J.R.; Wright, A.C.; et al. The G protein-coupled receptor repertoires of human and mouse. Proc. Natl. Acad. Sci. USA 2003, 100, 4903.
56. Takeda, S.; Kadowaki, S.; Haga, T.; Takaesu, H.; Mitaku, S. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 2002, 520, 97–101.
57. Jones, M.L.; Norman, J.E.; Morgan, N.V.; Mundell, S.J.; Lordkipanidze, M.; Lowe, G.C.; Daly, M.E.; Simpson, M.A.; Drake, S.; Watson, S.P.; et al. Diversity and impact of rare variants in genes encoding the platelet G protein-coupled receptors. Thromb. Haemost. 2015, 113, 826–837.
58. Law, D.A.; Nannizzi-Alaimo, L.; Phillips, D.R. Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation. J. Biol. Chem. 1996, 271, 10811–10815.
59. Sokol, J.; Skerenova, M.; Ivankova, J.; Simurda, T.; Stasko, J. Association of Genetic Variability in Selected Genes in Patients With Deep Vein Thrombosis and Platelet Hyperaggregability. Clin. Appl. Thromb. Hemost. Off. J. Int. Acad. Clin. Appl. Thromb. Hemost. 2018, 24, 1027–1032.
60. Baroni, G.; Banzato, A.; Bison, E.; Denas, G.; Zoppellaro, G.; Pengo, V. The role of platelets in antiphospholipid syndrome. Platelets 2017, 28, 762–766.
61. Biasiolo, A.; Pengo, V. Antiphospholipid antibodies are not present in the membrane of gel-filtered platelets of patients with IgG anticardiolipin antibodies, lupus anticoagulant and thrombosis. Blood Coagul. Fibrinolysis 1993, 4, 425–428.
62. Khamashta, M.A.; Harris, E.N.; Gharavi, A.E.; Derue, G.; Gil, A.; Vázquez, J.J.; Hughes, G.R. Immune mediated mechanism for thrombosis: Antiphospholipid antibody binding to platelet membranes. Ann. Rheum. Dis. 1988, 47, 849–854.
63. Forastiero, R.; Martinuzzo, M.; Carreras, L.O.; Maclouf, J. Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: Association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb. Haemost. 1998, 79, 42–45.
64. Espinola, R.G.; Pierangeli, S.S.; Gharavi, A.E.; Harris, E.N. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemost. 2002, 87, 518–522.
65. Galli, M.; Cortelazzo, S.; Viero, P.; Finazzi, G.; de Gaetano, G.; Barbui, T. Interaction between platelets and lupus anticoagulant. Eur. J. Haematol. 1988, 41, 88–94.
66. Galli, M.; Bevers, E.M.; Comfurius, P.; Barbui, T.; Zwaal, R.F. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br. J. Haematol. 1993, 83, 466–472.
67. Joseph, J.E.; Harrison, P.; Mackie, I.J.; Isenberg, D.A.; Machin, S.J. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br. J. Haematol. 2001, 115, 451–459.
68. Hell, L.; Lurger, K.; Mauracher, L.M.; Grilz, E.; Reumiller, C.M.; Schmidt, G.J.; Ercan, H.; Koder, S.; Assinger, A.; Basilio, J.; et al. Altered platelet proteome in lupus anticoagulant (LA)-positive patients-protein disulfide isomerase and NETosis as new players in LA-related thrombosis. Exp. Mol. Med. 2020, 52, 66–78.
69. Allen, K.L.; Fonseca, F.V.; Betapudi, V.; Willard, B.; Zhang, J.; McCrae, K.R. A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood 2012, 119, 884–893.
70. Lutters, B.C.; Derksen, R.H.; Tekelenburg, W.L.; Lenting, P.J.; Arnout, J.; de Groot, P.G. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2’. J. Biol. Chem. 2003, 278, 33831–33838.
71. Pennings, M.T.; Derksen, R.H.; van Lummel, M.; Adelmeijer, J.; VanHoorelbeke, K.; Urbanus, R.T.; Lisman, T.; de Groot, P.G. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: Glycoprotein Ibalpha and apolipoprotein E receptor 2’. J. Thromb. Haemost. 2007, 5, 369–377.
72. Satta, N.; Dunoyer-Geindre, S.; Reber, G.; Fish, R.J.; Boehlen, F.; Kruithof, E.K.; de Moerloose, P. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007, 109, 1507–1514.
73. Döring, Y.; Hurst, J.; Lorenz, M.; Prinz, N.; Clemens, N.; Drechsler, M.D.; Bauer, S.; Chapman, J.; Shoenfeld, Y.; Blank, M.; et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology 2010, 215, 230–241.
74. Hollerbach, A.; Muller-Calleja, N.; Ritter, S.; Hauser, F.; Canisius, A.; Orning, C.; Jurk, K.; Lackner, K.J. Platelet Activation by Antiphospholipid Antibodies Depends on Epitope Specificity and is Prevented by mTOR Inhibitors. Thromb. Haemost. 2019.
75. Nimpf, J.; Wurm, H.; Kostner, G.M. Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987, 63, 109–114.
76. Fu, H.; Zhao, J.; Xu, L.; Liu, K.; Wang, Y.; Chen, H.; Han, W.; Wang, J.; Wang, F.; Huang, X.; et al. Reduced β2-GPI is associated with increased platelet aggregation and activation in patients with prolonged isolated thrombocytopenia after allo-HSCT. Sci. China Life Sci. 2019, 62, 921–929.
77. Zhang, W.; Gao, F.; Lu, D.; Sun, N.; Yin, X.; Jin, M.; Liu, Y. Anti-β2 glycoprotein I antibodies in complex with β2 glycoprotein I induce platelet activation via two receptors: Apolipoprotein E receptor 2’ and glycoprotein I bα. Front. Med. 2016, 10, 76–84.
78. Vega-Ostertag, M.; Casper, K.; Swerlick, R.; Ferrara, D.; Harris, E.N.; Pierangeli, S.S. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum. 2005, 52, 1545–1554.
79. He, C.; Zhang, G.; Ouyang, H.; Zhang, P.; Chen, Y.; Wang, R.; Zhou, H. Effects of β2/aβ2 on oxLDL-induced CD36 activation in THP-1 macrophages. Life Sci. 2019, 239, 117000.
80. Shao, F.; Miao, Y.; Zhang, Y.; Han, L.; Ma, X.; Deng, J.; Jiang, C.; Kong, W.; Xu, Q.; Feng, J.; et al. B cell-derived anti-beta 2 glycoprotein I antibody contributes to hyperhomocysteinemia-aggravated abdominal aortic aneurysm. Cardiovasc. Res. 2019.
81. Shoenfeld, Y.; Blank, M.; Cervera, R.; Font, J.; Raschi, E.; Meroni, P.L. Infectious origin of the antiphospholipid syndrome. Ann. Rheum. Dis. 2006, 65, 2–6.
82. Galli, M.; Finazzi, G.; Bevers, E.M.; Barbui, T. Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995, 86, 617–623.
83. Silver, R.K.; Adler, L.; Hickman, A.R.; Hageman, J.R. Anticardiolipin antibody-positive serum enhances endothelial cell platelet-activating factor production. Am. J. Obstet. Gynecol. 1991, 165, 1748–1752.
84. Sammaritano, L.R.; Ng, S.; Sobel, R.; Lo, S.K.; Simantov, R.; Furie, R.; Kaell, A.; Silverstein, R.; Salmon, J.E. Anticardiolipin IgG subclasses: Association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum. 1997, 40, 1998–2006.
85. Nisar, S.P.; Jones, M.L.; Cunningham, M.R.; Mumford, A.D.; Mundell, S.J. Rare platelet GPCR variants: What can we learn? Br. J. Pharmacol. 2015, 172, 3242–3253.
86. Kamato, D.; Thach, L.; Bernard, R.; Chan, V.; Zheng, W.; Kaur, H.; Brimble, M.; Osman, N.; Little, P.J. Structure, Function, Pharmacology, and Therapeutic Potential of the G Protein, Gα/q,11. Front. Cardiovasc. Med. 2015, 2, 14.
87. Bergmeier, W.; Stefanini, L. Platelet ITAM signaling. Curr. Opin. Hematol. 2013, 20, 445–450.
88. Brandt, K.J.; Kruithof, E.K.; de Moerloose, P. Receptors involved in cell activation by antiphospholipid antibodies. Thromb. Res. 2013, 132, 408–413.
89. Armstrong, N.C.; Anderson, R.C.; McDermott, K.W. Reelin: Diverse roles in central nervous system development, health and disease. Int. J. Biochem. Cell Biol. 2019, 112, 72–75.
90. Urbanus, R.T.; Siegerink, B.; Roest, M.; Rosendaal, F.R.; de Groot, P.G.; Algra, A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: A case-control study. Lancet. Neurol. 2009, 8, 998–1005.
91. Arnaud, L.; Mathian, A.; Devilliers, H.; Ruffatti, A.; Tektonidou, M.; Forastiero, R.; Pengo, V.; Lambert, M.; Lefevre, G.; Martinez-Zamora, M.A.; et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun. Rev. 2015, 14, 192–200.
92. Saidi, S.; Mahjoub, T.; Almawi, W.Y. Lupus anticoagulants and anti-phospholipid antibodies as risk factors for a first episode of ischemic stroke. J. Thromb. Haemost. 2009, 7, 1075–1080.
93. Pasoto, S.G.; Chakkour, H.P.; Natalino, R.R.; Viana, V.S.; Bueno, C.; Lianza, A.C.; de Andrade, J.L.; Neto, M.L.; Fuller, R.; Bonfa, E. Lupus anticoagulant: A marker for stroke and venous thrombosis in primary Sjögren’s syndrome. Clin. Rheumatol. 2012, 31, 1331–1338.
94. De Mast, Q.; Molhoek, J.E.; van der Ven, A.J.; Gray, W.K.; de Groot, P.G.; Jusabani, A.; Mugusi, F.; Urbanus, R.T.; Walker, R.W. Antiphospholipid Antibodies and the Risk of Stroke in Urban and Rural Tanzania: A Community-Based Case-Control Study. Stroke 2016, 47, 2589–2595.
95. Kawakami, T.; Akashi, Y.J.; Soma, Y. Silent myocardial infarction subsequent to cutaneous polyarteritis nodosa in a patient with positive lupus anticoagulant. J. Am. Acad. Dermatol. 2011, 65, 442–443.
96. Landi, G.; Calloni, M.V.; Grazia Sabbadini, M.; Mannuccio Mannucci, P.; Candelise, L. Recurrent ischemic attacks in two young adults with lupus anticoagulant. Stroke 1983, 14, 377–379.
97. Mills, T.J.; Safford, R.E.; Kazmier, F.J. Myocardial infarction, persistent coronary artery thrombosis and lupus anticoagulant. Int. J. Cardiol. 1988, 21, 190–194.
98. Murai, K.; Sakata, K.; Gamou, T.; Nagata, Y.; Tada, H.; Shimojima, M.; Okada, H.; Hayashi, K.; Kawashiri, M.A. Acute myocardial infarction in a patient positive for lupus anticoagulant: A case report. BMC Cardiovasc. Disord. 2019, 19, 167.
99. Nojima, J.; Suehisa, E.; Akita, N.; Toku, M.; Fushimi, R.; Tada, H.; Kuratsune, H.; Machii, T.; Kitani, T.; Amino, N. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant. Br. J. Haematol. 1997, 96, 447–450.
100. Reynaud, Q.; Lega, J.C.; Mismetti, P.; Chapelle, C.; Wahl, D.; Cathébras, P.; Laporte, S. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun. Rev. 2014, 13, 595–608.
101. Borges, R.B.; Bodanese, L.C.; Mühlen, C.A.; Repetto, G.; Viehe, M.; Norman, G.L.; Staub, H.L. Anti-beta2-glycoprotein I autoantibodies and metabolic syndrome. Arq. Bras. Cardiol. 2011, 96, 272–276.
102. Kahles, T.; Humpich, M.; Steinmetz, H.; Sitzer, M.; Lindhoff-Last, E. Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke. Rheumatology 2005, 44, 1161–1165.
103. Ranzolin, A.; Bohn, J.M.; Norman, G.L.; Manenti, E.; Bodanese, L.C.; von Mühlen, C.A.; Staub, H.L. Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction. Arq. Bras. Cardiol. 2004, 83, 137–140.
104. Staub, H.L.; von Muhlen, C.A.; Norman, G.L. Beta2-glycoprotein I IgA antibodies and ischaemic stroke. Rheumatology 2006, 45, 645–646.
105. Vlachostergios, P.J.; Dufresne, F. Acute renal infarction associated with homozygous methylenetetrahydrofolate reductase mutation C677T and IgA beta-2-glycoprotein antibodies. Blood Coagul. Fibrinolysis 2015, 26, 583–585.
106. Arad, A.; Proulle, V.; Furie, R.A.; Furie, B.C.; Furie, B. β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 2011, 117, 3453–3459.
107. Zhang, S.; Wu, Z.; Zhang, W.; Zhang, F.; Li, Y.; Liu, Y. Clinical performance of non-criteria antibodies to phospholipids in Chinese patients with antiphospholipid syndrome. Clin. Chim. Acta 2019, 495, 205–209.
108. Murthy, V.; Willis, R.; Romay-Penabad, Z.; Ruiz-Limón, P.; Martínez-Martínez, L.A.; Jatwani, S.; Jajoria, P.; Seif, A.; Alarcón, G.S.; Papalardo, E.; et al. Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum. 2013, 65, 3186–3193.
109. Tortosa, C.; Cabrera-Marante, O.; Serrano, M.; Martínez-Flores, J.A.; Pérez, D.; Lora, D.; Morillas, L.; Paz-Artal, E.; Morales, J.M.; Pleguezuelo, D.; et al. Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies. PLoS ONE 2017, 12, e0178889.
110. Urbanski, G.; Yelnik, C.M.; Maillard, H.; Launay, D.; Dubucquoi, S.; Hachulla, E.; Hatron, P.Y.; Lambert, M. Antiphospholipid Syndrome With Isolated Isotype M Anticardiolipin and/or Anti-B2GPI Antibody Is Associated With Stroke. Stroke 2018, 49, 2770–2772.
111. Brey, R.L.; Abbott, R.D.; Curb, J.D.; Sharp, D.S.; Ross, G.W.; Stallworth, C.L.; Kittner, S.J. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: The honolulu heart program. Stroke 2001, 32, 1701–1706.
112. Matyja-Bednarczyk, A.; Swadźba, J.; Iwaniec, T.; Sanak, M.; Dziedzina, S.; Ćmiel, A.; Musiał, J. Risk factors for arterial thrombosis in antiphospholipid syndrome. Thromb. Res. 2014, 133, 173–176.
113. Pastori, D.; Bucci, T.; Triggiani, M.; Ames, P.R.J.; Parrotto, S.; Violi, F.; Pignatelli, P.; Farcomeni, A. Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis. Autoimmun. Rev. 2019, 18, 519–525.
114. Lopez, L.R.; Dier, K.J.; Lopez, D.; Merrill, J.T.; Fink, C.A. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am. J. Clin. Pathol. 2004, 121, 142–149.
115. Nojima, J.; Kuratsune, H.; Suehisa, E.; Kitani, T.; Iwatani, Y.; Kanakura, Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb. Haemost. 2004, 91, 967–976.
116. Okuma, H.; Kitagawa, Y.; Ishikawa, T.; Takagi, S. Study of phosphatidylserine-dependent anti-prothrombin antibody in cerebral infarction. Intern. Med. 2009, 48, 1351–1355.
117. Sciascia, S.; Sanna, G.; Murru, V.; Roccatello, D.; Khamashta, M.A.; Bertolaccini, M.L. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb. Haemost. 2014, 111, 354–364.